Steven Cohen Beam Therapeutics Inc. Transaction History

Point72 Asset Management, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$29.86 - $62.36 $725,598 - $1.52 Million	-24,300 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$53.73 - $82.16 $1.11 Million - $1.69 Million	-20,600 Reduced 45.88%	24,300 $1.39 Million
Q4 2021 Feb 14, 2022	BUY	$68.02 - $99.06 $3.05 Million - $4.45 Million	44,900 New	44,900 $3.58 Million
Q4 2020 Feb 16, 2021	SELL	$22.24 - $95.63 $5.52 Million - $23.8 Million	-248,417 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$19.0 - $30.57 $1.91 Million - $3.07 Million	100,579 Added 68.03%	248,417 $6.12 Million
Q2 2020 Aug 14, 2020	BUY	$15.26 - $28.66 $2.26 Million - $4.24 Million	147,838 New	147,838 $4.14 Million

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.78B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.